North America Exosome Therapeutic Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2021 –2028 |
 시장 규모(기준 연도) |
USD 327.63 Thousand |
 시장 규모(예측 연도) |
USD 1,140.63 Thousand |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
북미 엑소좀 치료제 시장, 유형별(천연 엑소좀, 하이브리드 엑소좀), 출처(중간엽줄기세포, 혈액, 체액, 소변, 수지상 세포, 타액, 모유 및 기타), 출처(T-림프구 및 기타), 요법(면역 요법, 유전자 요법, 화학 요법), 수송 용량(생체 거대 분자 및 소분자), 응용 분야(대사 장애, 종양학, 심장 질환, 신경학, 염증 장애, 장기 이식, 부인과 장애, 혈액 장애 및 기타), 투여 경로(비경구, 경구), 최종 사용자(연구 및 학술 기관, 병원 및 진단 센터), 국가별(미국 및 멕시코), 시장 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 북미 엑소솜 치료제 시장
북미 엑소좀 치료제 시장은 2022년에서 2029년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년의 예측 기간 동안 17.2%의 CAGR로 성장하고 있으며 2021년의 327.63만 달러에서 2020년까지 1,140.63만 달러에 도달할 것으로 예상한다고 분석했습니다. 만성 염증성 자가면역 질환의 유병률 증가와 엑소좀 치료제의 기술 개발은 예측 기간 동안 시장 수요를 촉진하는 주요 동인이 될 가능성이 높습니다.
엑소좀은 엔도솜으로 구성된 세포 유래 세포외 소포의 특정 종류이며 일반적으로 직경이 30~150nm로 가장 작은 유형의 세포외 소포입니다. 지질 이중층으로 보호되는 엑소좀은 원래 세포에서 유래한 복잡한 내용물이 들어 있는 세포외 환경으로 밀려납니다. 이 내용물에는 단백질, 지질, 메신저 리보핵산(mRNA), 미세소체 리보핵산(miRNA), 데옥시리보핵산(DNA)이 들어 있습니다. 엑소좀은 다중 소포체가 융합하여 세포외 공간으로 배출되는 방식으로 형성됩니다. 엑소좀은 자가면역 질환과 같은 다양한 만성 질환을 치료하는 데 사용되었습니다. 나노기술은 엑소좀과 같은 나노캐리어를 기반으로 암을 사전에 감지하는 데 새로운 통찰력을 보여주었습니다. 엑소좀은 치료적 개입에 적용할 수 있는 강력한 잠재력을 제공하므로, 엑소좀은 잠재적인 약물 운반체로 간주되어 왔습니다.
엑소좀은 두 가지 유형으로 구성되어 있습니다. 자연 엑소좀과 하이브리드 엑소좀입니다. 자연 엑소좀은 외인성 엑소좀과 자가 엑소좀으로 더 세분화됩니다. 자가 엑소좀은 암, 자가면역 질환 및 만성 염증성 질환의 치료를 위한 약물의 표적 전달을 위한 안전하고 효과적인 운반체입니다. 외인성 엑소좀은 다양한 세포의 엔도솜에서 방출되는 작은 세포외막 소포이며 활액액, 양수 및 정액과 같은 대부분의 체액에서 발견될 수 있습니다. 암에서 엑소좀은 전이성 확산, 약물 내성 및 새로운 혈관 형성에 중요한 역할을 합니다.
북미 엑소좀 치료제 시장 성장을 담당하는 주요 요인은 만성 염증성 질환의 증가, 엑소좀 치료제에 대한 연구 개발 활동의 증가, 엑소좀 치료제의 개발 및 생산을 위한 정부 자금 지원입니다. 게다가 신흥 경제권에서 엑소좀 치료제의 성장 잠재력과 항노화 요법의 사용 증가는 엑소좀 치료제 시장 성장을 뒷받침합니다. 그러나 비용 상승, 엄격한 규제, 엑소좀 치료제 사용 시 관찰되는 위험은 시장 성장을 방해할 수 있는 제약입니다. 의료비 지출 증가는 시장 성장에 수익성 있는 기회를 제공할 것으로 예상됩니다. 반면에 투자 증가와 엑소좀을 분리하기 위한 표준화된 절차의 부족, 필요한 전문 지식의 부족은 시장 성장에 영향을 미칠 것으로 예상되는 중요한 과제 중 일부입니다.
북미 엑소좀 치료제 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석과 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
북미 엑소솜 치료제 시장 범위 및 시장 규모
북미 엑소좀 치료제 시장은 유형, 출처, 치료법, 운반 능력, 응용 분야, 투여 경로 및 최종 사용자를 기준으로 7개의 주요 세그먼트로 분류됩니다.
- 유형에 따라 북미 엑소좀 치료제 시장은 천연 엑소좀과 하이브리드 엑소좀으로 구분됩니다. 2022년에는 천연 엑소좀 세그먼트가 엑소좀의 천연 소재와 치료를 위한 자가 엑소좀의 가용성으로 인해 북미 엑소좀 치료제 시장을 지배할 것으로 예상됩니다.
- On the basis of source, the North America exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva, milk, and others. In 2022, the mesenchymal stem cell segment is expected to dominate the North America exosome therapeutics market due to emerging applications of mesenchymal stem cells and expansion of the pipeline and clinical studies of mesenchymal stem cell-based products.
- On the basis of therapy, the North America exosome therapeutics market is segmented into immunotherapy, gene therapy, and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the North America exosome therapeutics market due to ease of convenience, high accuracy, and improvement in long-term survival rate.
- On the basis of transporting capacity, the North America exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the North America exosome therapeutics market due to the presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders, cancer, and ease of availability.
- On the basis of application, the North America exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. In 2022, the metabolic disorders segment is expected to dominate the North America exosome therapeutics market due to the increase in cases of metabolic disorders and availability of exosome therapeutics in diagnostic laboratories in the U.S. for the treatment of metabolic disorders.
- On the basis of route of administration, the North America exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the North America exosome therapeutics market due to enhanced bioavailability and rapid onset action.
- On the basis of end user, theNorth America exosome therapeutics market is segmented into research and academic institutes, hospitals, and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the North America exosome therapeutics market due to the rise in research and development of exosomes and support from the government in funding.
North America Exosome Therapeutics Market Country Level Analysis
North America exosome therapeutics market is analyzed, and market size information is provided by type, source, therapy, transporting capacity, application, route of administration, and end user.
The countries covered in the North America exosome therapeutics market are the U.S. and Mexico.
- In 2021, the U.S. is expected to dominate due to the presence of the largest consumer market with high GDP. Moreover, the U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products, including products for exosome therapeutics due to the presence of major market players and increased technological advancement in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growth Potential For Exosome Therapeutics In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The North America Exosome therapeutics market
North America exosome therapeutics market also provides you with detailed market analysis for every country growth in a particular industry with the exosome therapeutics sales. The impact of advancement in the exosome therapeutics and changes in regulatory scenarios with their support for the exosome therapeutics market. The data is available for the historic period 2011 to 2020.
Competitive Landscape and North America Exosome Therapeutics Market Share Analysis
North America exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the exosome therapeutics market.
Some of the major companies providing the exosome therapeutics are Stem Cells Group, Exosome Sciences, AEGLE Therapeutics, Capricor Therapeutics, Avalon Globocare Corp, CODIAK, Kimera Labs, Jazz Pharmaceuticals, Inc., and EV Therapeutics, among others.
DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for North America exosome therapeutics are bridging the gap for the treatment of inflammatory diseases.
For instance,
- 2021년 4월, EV Therapeutics는 미네소타 대학교 의과대학과 협력하여 대장암 치료를 위한 엑소좀 기반 치료 전략을 출시했습니다. 엑소좀 기반 치료 전략의 출시는 대장암으로 고통받는 환자를 적시에 치료하기 위해 진단 센터와 병원에서 엑소좀 기반 치료 전략을 사용할 수 있도록 보장합니다.
시장 참여자들의 협력, 합작투자 및 기타 전략은 엑소좀 치료 시장에서 기업 시장을 강화하고 있으며, 이를 통해 기업이 북미 엑소좀 치료 시장에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PIPELINE ANALYSIS
6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES
7.1.2 RISE IN INCIDENCE OF ONCOLOGY DISEASES
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME THERAPEUTICS
7.1.4 RISE IN RESEARCH AND DEVELOPMENT ACTIVITIES, INVOLVED IN EXOSOME THERAPEUTICS
7.1.5 GOVERNMENT FUNDING FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOME THERAPEUTICS
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE EXOSOME THERAPEUTICS
7.2.2 LACK OF AUTHENTICATION REQUIREMENTS FOR ISOLATION OF EXOSOMES
7.2.3 RISKS OBSERVED WHILE USING EXOSOME THERAPEUTICS
7.2.4 UNMET MEDICAL NEEDS
7.3 OPPORTUNITIES
7.3.1 INCREASE USE OF ANTI-AGING THERAPY
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISE IN HEALTHCARE EXPENDITURE
7.3.4 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES
7.3.5 PROGRESSING THERAPEUTIC VALUE OF EXOSOME
7.4 CHALLENGES
7.4.1 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME
7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES
8 IMPACT OF COVID-19 ON NORTH AMERICA EXOSOME THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS BY MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE
9.1 OVERVIEW
9.2 NATURAL EXOSOMES
9.2.1 AUTOLOGOUS EXOSOMES
9.2.2 EXOGENOUS EXOSOMES
9.3 HYBRID EXOSOMES
10 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 MESENCHYMAL STEM CELLS
10.3 BLOOD
10.3.1 T-LYMPHOCYTES
10.3.2 OTHERS
10.4 BODY FLUIDS
10.4.1 AMNIOTIC FLUID
10.4.2 SEMEN
10.4.3 SYNOVIAL FLUID
10.4.4 OTHERS
10.5 URINE
10.6 DENDRITIC CELLS
10.7 SALIVA
10.8 MILK
10.9 OTHERS
11 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY
11.1 OVERVIEW
11.2 IMMUNOTHERAPY
11.3 GENE THERAPY
11.4 CHEMOTHERAPY
12 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY
12.1 OVERVIEW
12.2 BIO MACROMOLECULES
12.2.1 NUCLEIC ACIDS
12.2.2 PROTEINS
12.2.3 PEPTIDES
12.3 SMALL MOLECULES
13 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 METABOLIC DISORDERS
13.3 ONCOLOGY
13.3.1 NON-SMALL CELL LUNG CANCER
13.3.2 BREAST CANCER
13.3.3 GASTRIC CANCER
13.3.4 HEAD AND NECK CANCER
13.3.5 OTHERS
13.4 CARDIAC DISORDERS
13.5 NEUROLOGY
13.5.1 ALZHEIMER'S DISEASE
13.5.2 PARKINSON'S DISEASE
13.5.3 OTHERS
13.6 INFLAMMATORY DISORDERS
13.7 ORGAN TRANSPLANTATION
13.8 GYNECOLOGY DISORDERS
13.9 BLOOD DISORDERS
13.1 OTHERS
14 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PARENTERAL
14.3 ORAL
15 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 RESEARCH AND ACADEMIC INSTITUTES
15.3 HOSPITALS
15.4 DIAGNOSTIC CENTERS
16 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 MEXICO
17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 COMPANY PROFILE
18.1 KIMERA LABS
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 STEM CELLS GROUP
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 AEGLE THERAPEUTICS
18.3.1 COMPANY SNAPSHOT
18.3.2 PRODUCT PORTFOLIO
18.3.3 RECENT DEVELOPMENTS
18.4 AVALON GLOBOCARE CORP.(2021)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 CAPRICOR THERAPEUTICS (2021)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 CODIAK (2021)
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 EXOSOME SCIENCES (A SUBSIDIARY OF AETHLON MEDICAL) (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS NO RECENT DEVELOPMENTS
18.8 EXOPHARM
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 EVOX THERAPEUTICS
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENTS
18.1 EV THERAPEUTICS
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 JAZZ PHARMACEUTICALS, INC
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 RENEURON GROUP PLC
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 STEM CELL MEDICINE
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
TABLE 1 NORTH AMERICA EXOSOME THERAPEUTICSMARKET, PIPELINE ANALYSIS
TABLE 2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA HYBRID EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 12 NORTH AMERICA URINE IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA DENDRITIC CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA SALIVA IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA MILK IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 16 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)
TABLE 18 NORTH AMERICA IMMUNOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 19 NORTH AMERICA GENE THERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 20 NORTH AMERICA CHEMOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 22 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 24 NORTH AMERICA SMALL MOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 25 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 26 NORTH AMERICA METABOLIC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA ONCOLOGY IN NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 29 NORTH AMERICA CARDIAC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA BLOOD DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA PARENTERAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA ORAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA RESEARCH AND ACADEMIC INSTITUTES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA HOSPITALS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA BIO MACROOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 58 U.S. EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 59 U.S. NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 60 U.S. EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 61 U.S. BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 62 U.S.BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 63 U.S. EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)
TABLE 64 U.S. EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 65 U.S. BIO MACROMOLECULES EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 66 U.S. EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 67 U.S. ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 68 U.S. NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 69 U.S. EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 70 U.S. EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 71 MEXICO EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 72 MEXICO NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 MEXICO EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 74 MEXICO BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 75 MEXICO BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)
TABLE 76 MEXICO EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)
TABLE 77 MEXICO EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 78 MEXICO BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
TABLE 79 MEXICO EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 80 MEXICO ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 81 MEXICO NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)
TABLE 82 MEXICO EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 83 MEXICO EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)
그림 목록
FIGURE 1 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASED PREVALENCE OF AUTOIMMUNE DISORDERS, LYME DISEASES, INCIDENCE OF CANCER AND RISE IN TECHNOLOGICAL ADVANCEMENTS IS EXPECTED TO DRIVE THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET FROM 2022 TO 2029
FIGURE 12 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA EXOSOME THERAPEUTICS MARKET
FIGURE 14 THE PREVALENCE OF MULTIPLE SCLEROSIS IN WORLD HEALTH ORGANISATION (WHO) REGIONS IN 2020.
FIGURE 15 INCIDENCE RATE OF CANCER IN AUSTRALIA AND OTHER COUNTRIES (2020)
FIGURE 16 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, 2020-2029 (USD THOUSAND)
FIGURE 18 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2021
FIGURE 21 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2020-2029 (USD THOUSAND)
FIGURE 22 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2021
FIGURE 25 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2020-2029 (USD THOUSAND)
FIGURE 26 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, LIFELINE CURVE
FIGURE 28 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2021
FIGURE 29 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)
FIGURE 30 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, LIFELINE CURVE
FIGURE 32 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2021
FIGURE 33 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2020-2029 (USD THOUSAND)
FIGURE 34 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 36 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 37 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
FIGURE 38 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 40 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, 2021
FIGURE 41 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, 2020-2029 (USD THOUSAND)
FIGURE 42 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 45 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 46 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 48 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE (2022-2029)
FIGURE 49 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
